{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T20:45:16Z","timestamp":1786653916407,"version":"build-2736575974"},"reference-count":33,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,6]],"date-time":"2026-04-06T00:00:00Z","timestamp":1775433600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","nmcd-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Nutrition, Metabolism and Cardiovascular Diseases"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.numecd.2026.104728","type":"journal-article","created":{"date-parts":[[2026,4,3]],"date-time":"2026-04-03T01:56:28Z","timestamp":1775181388000},"page":"104728","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Effect of proprotein convertase subtilisin kexin 9 inhibitors on platelet aggregation in patients with and without diabetes"],"prefix":"10.1016","volume":"36","author":[{"given":"Mario","family":"Crisci","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3885-5093","authenticated-orcid":false,"given":"Federica","family":"Ilardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachele","family":"Manzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felice","family":"Gragnano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberta","family":"Paolillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Giugliano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Orlando","family":"Piro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emanuele","family":"Cigala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ida","family":"Monteforte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veronica","family":"D'Oria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enzo","family":"Venga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Marotta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Salvato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Calabr\u00f2","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Esposito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emilio","family":"Di Lorenzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marisa","family":"De Feo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.numecd.2026.104728_bib1","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1007\/s40256-015-0153-0","article-title":"Evolocumab: a review in hyperlipidemia","volume":"16","author":"Keating","year":"2016","journal-title":"Am J Cardiovasc Drugs"},{"key":"10.1016\/j.numecd.2026.104728_bib2","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1002\/biof.1619","article-title":"Beyond cholesterol metabolism: the pleiotropic effects of proprotein convertase subtilisin\/kexin type 9 (PCSK9). Genetics, mutations, expression, and perspective for long-term inhibition","volume":"46","author":"Cesaro","year":"2020","journal-title":"Biofactors"},{"issue":"6","key":"10.1016\/j.numecd.2026.104728_bib3","doi-asserted-by":"crossref","first-page":"57","DOI":"10.3892\/ijmm.2024.5381","article-title":"Effects of PCSK9 on thrombosis and haemostasis in a variety of metabolic states: lipids and beyond","volume":"53","author":"Chong","year":"2024","journal-title":"Int J Mol Med"},{"key":"10.1016\/j.numecd.2026.104728_bib4","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1016\/j.ijcard.2016.10.084","article-title":"Association of PCSK9 with platelet reactivity in patients with acute coronary syndrome treated with prasugrel or ticagrelor: the PCSK9-REACT study","volume":"227","author":"Navarese","year":"2017","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.numecd.2026.104728_bib5","doi-asserted-by":"crossref","first-page":"76","DOI":"10.5551\/jat.25841","article-title":"The relationship between the plasma PCSK9 levels and platelet indices in patients with stable coronary artery disease","volume":"22","author":"Li","year":"2015","journal-title":"J Atherosclerosis Thromb"},{"key":"10.1016\/j.numecd.2026.104728_bib6","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1186\/s12933-022-01519-3","article-title":"Association of PCSK9 with inflammation and platelet activation markers and recurrent cardiovascular risks in STEMI patients undergoing primary PCI with or without diabetes","volume":"21","author":"Song","year":"2022","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.numecd.2026.104728_bib7","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1186\/s12933-020-01142-0","article-title":"Association of circulating PCSK9 concentration with cardiovascular metabolic markers and outcomes in stable coronary artery disease patients with or without diabetes: a prospective, observational cohort study","volume":"19","author":"Peng","year":"2020","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.numecd.2026.104728_bib8","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1161\/CIRCULATIONAHA.120.046928","article-title":"Cangrelor, Tirofiban, and chewed or standard prasugrel regimens in patients with ST-Segment-Elevation myocardial infarction: primary results of the FABOLUS-FASTER trial","volume":"142","author":"Gargiulo","year":"2020","journal-title":"Circulation"},{"key":"10.1016\/j.numecd.2026.104728_bib9","doi-asserted-by":"crossref","first-page":"4359","DOI":"10.1093\/eurheartj\/ehaf190","article-title":"Focused update of the 2019 ESC\/EAS guidelines for the management of dyslipidaemias","volume":"46","author":"Mach","year":"2025","journal-title":"Eur Heart J"},{"key":"10.1016\/j.numecd.2026.104728_bib10","first-page":"491","article-title":"Complete revascularization in acute and chronic coronary syndrome","volume":"38","author":"Ilardi","year":"2020","journal-title":"Cardiol Clin"},{"key":"10.1016\/j.numecd.2026.104728_bib11","doi-asserted-by":"crossref","first-page":"3227","DOI":"10.1093\/eurheartj\/ehab484","article-title":"ESC guidelines on cardiovascular disease prevention in clinical practice","volume":"42","author":"Visseren","year":"2021","journal-title":"Eur Heart J"},{"key":"10.1016\/j.numecd.2026.104728_bib12","doi-asserted-by":"crossref","first-page":"4043","DOI":"10.1093\/eurheartj\/ehad192","article-title":"ESC guidelines for the management of cardiovascular disease in patients with diabetes","volume":"44","author":"Marx","year":"2023","journal-title":"Eur Heart J"},{"key":"10.1016\/j.numecd.2026.104728_bib13","doi-asserted-by":"crossref","first-page":"660","DOI":"10.2459\/JCM.0000000000000981","article-title":"Impact of chronic kidney disease on platelet aggregation in patients with acute coronary syndrome","volume":"21","author":"Ilardi","year":"2020","journal-title":"J Cardiovasc Med (Hagerstown)"},{"key":"10.1016\/j.numecd.2026.104728_bib14","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.amjcard.2018.03.004","article-title":"Effects of carvedilol versus metoprolol on platelet aggregation in patients with acute coronary syndrome: the PLATE-BLOCK study","volume":"122","author":"Ilardi","year":"2018","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.numecd.2026.104728_bib15","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.ijcard.2021.10.138","article-title":"Prevalence and clinical implications of eligibility criteria for prolonged dual antithrombotic therapy in patients with PEGASUS and COMPASS phenotypes: insights from the START-ANTIPLATELET registry","volume":"345","author":"Cesaro","year":"2021","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.numecd.2026.104728_bib16","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1177\/0003319718760917","article-title":"Epidemiology and management of patients with acute coronary syndromes in contemporary real-world practice: evolving trends from the EYESHOT study to the START-ANTIPLATELET registry","volume":"69","author":"Calabr\u00f2","year":"2018","journal-title":"Angiology"},{"key":"10.1016\/j.numecd.2026.104728_bib17","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.117.007322","article-title":"Rac1 modulates endothelial function and platelet aggregation in diabetes mellitus","volume":"7","author":"Schiattarella","year":"2018","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.numecd.2026.104728_bib18","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/s12979-018-0138-3","article-title":"Different age-independent effects of nutraceutical combinations on endothelium-mediated coronary flow reserve","volume":"15","author":"Esposito","year":"2018","journal-title":"Immun Ageing"},{"key":"10.1016\/j.numecd.2026.104728_bib19","doi-asserted-by":"crossref","first-page":"404","DOI":"10.2174\/1570161115666170201114835","article-title":"Von Willebrand Factor and Cardiovascular Disease: from a Biochemical Marker to an Attractive Therapeutic Target","volume":"15","author":"Gragnano","year":"2017","journal-title":"Curr Vasc Pharmacol"},{"key":"10.1016\/j.numecd.2026.104728_bib20","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1055\/s-0040-1713375","article-title":"Platelet inhibition with ticagrelor versus clopidogrel in diabetic patients after percutaneous coronary intervention for chronic coronary syndromes","volume":"120","author":"Liu","year":"2020","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.numecd.2026.104728_bib21","doi-asserted-by":"crossref","first-page":"3175","DOI":"10.1038\/s41598-020-59663-3","article-title":"Factors associated with platelet reactivity during dual antiplatelet therapy in patients with diabetes after acute coronary syndrome","volume":"10","author":"Tatarunas","year":"2020","journal-title":"Sci Rep"},{"key":"10.1016\/j.numecd.2026.104728_bib22","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1093\/ehjcvp\/pvad019","article-title":"The efficacy of PCSK9 inhibitors on major cardiovascular events and lipid profile in patients with diabetes: a systematic review and meta-analysis of randomized controlled trials","volume":"9","author":"Imbalzano","year":"2023","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"10.1016\/j.numecd.2026.104728_bib23","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1161\/CIRCULATIONAHA.112.095554","article-title":"Immediate antioxidant and antiplatelet effect of atorvastatin via inhibition of Nox2","volume":"126","author":"Pignatelli","year":"2012","journal-title":"Circulation"},{"key":"10.1016\/j.numecd.2026.104728_bib24","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1177\/0300060516675681","article-title":"Effects of atorvastatin on ADP-, arachidonic Acid-, Collagen-, and epinephrine-induced platelet aggregation","volume":"45","author":"Zhao","year":"2017","journal-title":"J Int Med Res"},{"key":"10.1016\/j.numecd.2026.104728_bib25","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1002\/clc.22709","article-title":"Platelet reactivity in response to loading dose of atorvastatin or rosuvastatin in patients with stable coronary disease before percutaneous coronary intervention: the STATIPLAT randomized study","volume":"40","author":"Godino","year":"2017","journal-title":"Clin Cardiol"},{"key":"10.1016\/j.numecd.2026.104728_bib26","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/j.numecd.2019.09.012","article-title":"Platelet function and activation markers in primary hypercholesterolemia treated with Anti-PCSK9 monoclonal antibody: a 12-Month Follow-Up","volume":"30","author":"Barale","year":"2020","journal-title":"Nutr Metabol Cardiovasc Dis"},{"key":"10.1016\/j.numecd.2026.104728_bib27","first-page":"1254","article-title":"Impact of evolocumab on the pharmacodynamic profiles of clopidogrel in patients with atherosclerotic cardiovascular disease: a randomised, double-blind, placebo-controlled study","volume":"18","author":"Franchi","year":"2023","journal-title":"EuroIntervention"},{"key":"10.1016\/j.numecd.2026.104728_bib28","doi-asserted-by":"crossref","first-page":"76","DOI":"10.4330\/wjc.v9.i2.76","article-title":"PCSK9 inhibitors: a new era of lipid lowering therapy","volume":"9","author":"Chaudhary","year":"2017","journal-title":"World J Cardiol"},{"key":"10.1016\/j.numecd.2026.104728_bib29","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.pcad.2009.05.001","article-title":"Aspirin resistance","volume":"52","author":"Tantry","year":"2009","journal-title":"Prog Cardiovasc Dis"},{"key":"10.1016\/j.numecd.2026.104728_bib30","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1016\/j.jacc.2017.07.743","article-title":"Relationship of PCSK9 and urinary thromboxane excretion to cardiovascular events in patients with atrial fibrillation","volume":"70","author":"Pastori","year":"2017","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.numecd.2026.104728_bib31","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.thromres.2020.07.049","article-title":"Endothelial function improvement in patients with familial hypercholesterolemia receiving PCSK-9 inhibitors on top of maximally tolerated lipid lowering therapy","volume":"194","author":"Di Minno","year":"2020","journal-title":"Thromb Res"},{"key":"10.1016\/j.numecd.2026.104728_bib32","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJMoa1615664","article-title":"Evolocumab and clinical outcomes in patients with cardiovascular disease","volume":"376","author":"Sabatine","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.numecd.2026.104728_bib33","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1056\/NEJMoa1801174","article-title":"Alirocumab and cardiovascular outcomes after acute coronary syndrome","volume":"379","author":"Schwartz","year":"2018","journal-title":"N Engl J Med"}],"container-title":["Nutrition, Metabolism and Cardiovascular Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0939475326001900?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0939475326001900?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T19:56:21Z","timestamp":1786650981000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0939475326001900"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":33,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["S0939475326001900"],"URL":"https:\/\/doi.org\/10.1016\/j.numecd.2026.104728","relation":{},"ISSN":["0939-4753"],"issn-type":[{"value":"0939-4753","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effect of proprotein convertase subtilisin kexin 9 inhibitors on platelet aggregation in patients with and without diabetes","name":"articletitle","label":"Article Title"},{"value":"Nutrition, Metabolism and Cardiovascular Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.numecd.2026.104728","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V. on behalf of The Italian Diabetes Society, the Italian Society for the Study of Atherosclerosis, the Italian Society of Human Nutrition and the Department of Clinical Medicine and Surgery, Federico II University.","name":"copyright","label":"Copyright"}],"article-number":"104728"}}